Last reviewed · How we verify
NMBAs
At a glance
| Generic name | NMBAs |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol (NA)
- Effects on Biotrauma of NMBAs and PP Association During ARDS (NA)
- Negative Predictive Value and NIC of Beta-Lactam Antibiotics. (NA)
- "Effects of Neuromuscular Blocking Agents on End Expiratory Lung Volume During Moderate-severe ARDS"
- Sedation and Ventilator Weaning Protocol in PICU (NA)
- Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation (NA)
- The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMBAs CI brief — competitive landscape report
- NMBAs updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI